- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- October 2024
- 145 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Drug Pipelines
- March 2025
- 180 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 180 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 183 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 183 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 187 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 196 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- July 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- December 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 276 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 150 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 192 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 181 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 179 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 142 Pages
Global
From €4706EUR$4,950USD£3,953GBP

The JAK Inhibitor market is a subset of the larger Immune Disorders Drugs market. JAK Inhibitors are a type of drug used to treat a variety of immune-related disorders, such as rheumatoid arthritis, psoriasis, and Crohn's disease. These drugs work by blocking the activity of Janus kinase (JAK) enzymes, which are involved in the body's inflammatory response. JAK Inhibitors are typically taken orally, and are often used in combination with other medications.
The JAK Inhibitor market is highly competitive, with a number of large pharmaceutical companies vying for market share. Some of the major players in the market include AbbVie, Pfizer, Novartis, and Johnson & Johnson. Other companies, such as Celgene, Merck, and Eli Lilly, are also active in the market. Show Less Read more